Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GENK vs COYA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

COYA Captures Overall Composite Edge (64.4 BUY vs 47.6 HOLD), While GENK Leads 5–1 on Growth & Valuation Pillars

COYA Overall Winner 6-Pillar Tally: GENK 5 – 1 COYA Matrix Metrics: GENK 2 – 6 COYA

As of Nov 20, 2026, Coya Therapeutics, Inc. (COYA) captures the overall head-to-head institutional edge over GEN Restaurant Group, Inc. (GENK) on higher Unified Composite conviction (64.4/100 BUY vs. 47.6/100 HOLD) after splitting the core matrix 6–2 (led by Options & Positioning), while GENK wins 5–1 across the 6-pillar growth and valuation breakdown. GENK trades at $0.81 (N/M Forward P/E, -11.3% operating margin) versus COYA at $2.95 (N/M Forward P/E, -636.8% operating margin).

  • Growth vs. Quality Trade-Off: COYA earns the overall head-to-head edge with a stronger Unified Composite Score (64.4/100 BUY vs. GENK 47.6/100 HOLD) and 1.96β · 81% Vol risk profile, whereas GENK leads top-line expansion (-3.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GENK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile COYA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GENK vs COYA
GENK NASDAQ
GEN Restaurant Group, Inc. Class A Common Stock
Retail-Eating Places
$0.81
-12.9% 1D
Market Cap $34.4M
TTM Revenue $208M
Forward P/E N/M
Beta / 30D Vol 0.91β · 132% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $1.25 · SMA50: $1.49
COYA NASDAQ Head-to-Head Winner
Coya Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$2.95
-1.01% 1D
Market Cap $69.9M
TTM Revenue $4.7M
Forward P/E N/M
Beta / 30D Vol 1.96β · 81% Vol
Unified Composite Score
64.4 / 100 BUY
Tech 85.0 Fund 69.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.0%), weak momentum, RSI 33
RSI-14: 32.9 · SMA20: $3.30 · SMA50: $4.14

6-Pillar Scorecard Institutional Category Breakdown (GENK 5 – 1 COYA)

Columns: Metric · GENK · COYA
1. Valuation Multiples GENK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.2x 14.9x
2. Growth & Scale GENK
Revenue Growth (YoY) -3.3% -93.4%
Earnings Growth (YoY) -93.6% +0.0%
TTM Revenue (USD) $208M $4.7M
Market Cap $34.4M $69.9M
3. Profitability & Quality GENK
Gross Margin 8.7% N/A
Operating Margin -11.3% -636.8%
Net Profit Margin -2.3% 0.0%
Return on Equity (ROE) -117.1% -99.2%
4. Balance Sheet & Cash Flow GENK
Cash Generation (TTM) -$14M EBITDA -$22M
Cash Flow Margin -6.7% EBITDA Mgn N/A
Net Cash / Leverage $1.78 Book/Sh · -117.1% ROE $1.43 Book/Sh · -99.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning COYA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 393.8% (46th %ile)
Put/Call OI Skew N/A 0.28x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat GENK
OpEx & R&D Intensity 20.0% of Rev ($42M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Restaurants Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GENK (2) vs COYA (6)
Institutional Metric GENK COYA Criterion Row Edge
Market Capitalization
Scale
$34.4M $69.9M Larger Scale COYA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-3.3% -93.4% Higher Growth GENK
Operating Margin (TTM)
Profitability
-11.3% -636.8% Higher Margin GENK
Net Profit Margin
Profitability
-2.3% 0.0% Higher Margin COYA
Return on Equity (ROE)
Capital Efficiency
-117.1% -99.2% Higher ROE COYA
52-Week Range Position
Momentum
0% ($1–$3) 6% ($3–$7) Stronger Trend COYA
Beta / 30D Volatility
Risk Regime
0.91β · 132% Vol 1.96β · 81% Vol Lower Realized Risk COYA
Unified Institutional Score
Composite Signal
47.6 / 100 (HOLD) 64.4 / 100 (BUY) Higher Composite COYA
Trailing 12M Revenue (USD)
Operating Scale
$208M $4.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
8.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · 14.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$14M EBITDA ($1.78 Book/Sh · -117.1% ROE) -$22M ($1.43 Book/Sh · -99.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COYA +19.67 pp
GENK: -48.41% · COYA: -28.74%
3M Horizon COYA +18.36 pp
GENK: -58.88% · COYA: -40.52%
6M Horizon COYA +24.84 pp
GENK: -63.51% · COYA: -38.67%
1Y Horizon COYA +17.62 pp
GENK: -66.67% · COYA: -49.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GENK vs COYA. Trailing 12-month operating profitability (GENK -11.3% vs COYA -636.8%) and valuation multiples (GENK N/M vs COYA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GENK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$208M
Gross Margin8.7%
Op. Margin-11.3%
ROE / Fwd P/E-117.1% · N/M
COYA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross MarginN/A
Op. Margin-636.8%
ROE / Fwd P/E-99.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GENK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GENK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COYA BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 393.8%
IV Percentile 46th %ile
Put/Call OI Skew 0.28x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COYA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GENK Moat Profile Cyclical / Execution-Driven Positioning
Restaurants Operator
Competes within the Restaurants value chain with $34.4M market capitalization and -11.3% operating margin.
OpEx & R&D Reinvestment 20.0% of Rev ($42M)
90D Engineering Disclosures 0 Published
COYA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and -636.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GENK vs COYA Key Questions & Quantitative Answers

As of Nov 20, 2026, Coya Therapeutics, Inc. (COYA) captures the overall head-to-head institutional edge over GEN Restaurant Group, Inc. (GENK) on higher Unified Composite conviction (64.4/100 BUY vs. 47.6/100 HOLD) after splitting the core matrix 6–2 (led by Options & Positioning), while GENK wins 5–1 across the 6-pillar growth and valuation breakdown. GENK trades at $0.81 (N/M Forward P/E, -11.3% operating margin) versus COYA at $2.95 (N/M Forward P/E, -636.8% operating margin). Growth vs. Quality Trade-Off: COYA earns the overall head-to-head edge with a stronger Unified Composite Score (64.4/100 BUY vs. GENK 47.6/100 HOLD) and 1.96β · 81% Vol risk profile, whereas GENK leads top-line expansion (-3.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GENK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9); meanwhile COYA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GENK leads the Growth & Scale pillar: GENK posts -3.3% YoY revenue growth and -93.6% YoY earnings growth on $208M TTM revenue (8.7% gross margin, -11.3% operating margin), compared with COYA at -93.4% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (N/A gross margin, -636.8% operating margin). On trailing 12-month operating scale, GENK generates $208M in USD-normalized revenue versus $4.7M for COYA. In operating R&D and SG&A reinvestment, GENK deploys 20.0% of Rev ($42M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COYA.

GENK screens cheaper on headline valuation multiples. GENK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-6.7% EBITDA margin), whereas COYA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GENK (-117.1% ROE) versus COYA (-99.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GENK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.91β · 132% Vol realized risk). By comparison, COYA carries 393.8% implied volatility (46th %ile, Balanced (25th–60th %ile)), a 0.28x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.96β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.